Ledipasvir increases tenofovir (TDF) exposures. In individuals taking EVG/COBI/TDF/FTC or TDF with a ritonavir (RTV)-boosted HIV PI, higher TDF exposures may increase the risk of renal toxicity.
To evaluate the renal safety of 12 or 24 weeks of Sofosbuvir/Ledispasvir (SOF/LDV), according to boosted TDF exposure, in a cohort of 159 HIV/HCV co-infected patients at a tertiary center in Madrid (Spain). We included all consecutive patients with complete renal function and overall safety follow-up data during therapy.
From March 2015, 159 patients started SOF/LDV. HAART included TDF/FTC in 53 (33%); of them, 35 (66%) patients did not receive a boosted TDF regimen, whereas a “boosted TDF” regimen was used in 18 (34%): EVG/COBI/FTC/TDF in 10 (55%), FTC/TDF plus a RTV-boosted PI in 7 (39%), and simultaneous EVG/COBI/FTC/TDF and darunavir in one (5%).
At baseline there were no significant differences with respect to demographic data, genotype or HCV viral load, eGFR (CKD-EPI), or % of subjects with eGFR<70mil/min. Of note, more patients on boosted TDF received a 24w course of SOF/LDV (28% vs 0%, p=0.005).
During therapy we did not find significant differences in Creatinine or eGFR between both groups, nor in the rates of eGFR<70ml/min at the end of SOF/LDV: 2 patients (6%) in the non-boosted TDF group vs 3 patients (17%) in the TDF-boosted group (p=0.32). None of the 53 patients on TDF reached eGFR below 50ml/min, and only one patient on boosted-TDF (5%) stopped TDF due to renal impairment after 74 days of therapy (eGFR 56 ml/min).
In our “real life” population, SOF/LDV did not significantly worsen renal function in patients on “boosted TDF” (EVG/COBI/FTC/TDF or TDF with a RTV-boosted HIV PI).